Researcher Spotlight: Owhofasa Agbedia, MBBS, MPH UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER Chimeric antigen receptor (CAR)-T cell therapies involve the re-engineering of a patient’s ownimmune cells to help them find and fight cancer cells within the body. This treatment…
Researcher Spotlight: Samuel Yamshon, MD JOAN & SANFORD I. WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY In recent years, there has been substantial research interest in harnessing the power of the body’s own immune system to help fight lymphoma. This type…
Researcher Spotlight: Harsh Shah, DO The University of Utah Stedman Family Scholar The future of lymphoma treatment is rapidly evolving, and investigator-initiated clinical trials are helping to pave the way toward improved treatment approaches. Dr. Shah’s LRF research is focused…
Researcher Spotlight: Helen Ma, MDStephanie A. Gregory Distinguished Scholar THE REGENTS OF THE UNIVERSITY OF CALIFORNIA Veterans who have been involved in combat over the last several decades have been potentially exposed to a variety of carcinogenic elements, such as…
Researcher Spotlight: David Qualls, MD Memorial Sloan Kettering Cancer Center Immunotherapies in lymphoma aim to activate the patient’s own immune system to help target and destroy lymphoma cells. While effective, the impact of these types of therapies is often hampered…
Researcher Spotlight: Dai Chihara, MD UNIVERSITY OF TEXAS M.D. ANDERSON CANCER CENTER Phase I trials are the first step in transitioning new drugs from the bench to the clinic. These trials are intended to evaluate the safety and tolerability of…
Researcher Spotlight: Hans-Guido Wendel, MD Memorial Sloan Kettering Cancer Center Mutations in epigenetic regulators of gene expression are common in follicular lymphoma (FL), which result in altered expression of hundreds of genes. Throughcollaborative efforts with clinical and research leaders at…
Researcher Spotlight: David Scott, MBCHB, PhD BC Cancer The disease course for follicular lymphoma (FL) is highly variable, and while many patients respond to treatment, some may experience relapse or evolution of disease into a more aggressive form of lymphoma.…
Researcher Spotlight: Abner Louissaint, MD, PhD Massachussetts General Hospital Follicular lymphoma (FL) is unique among lymphomas in that there are many interactions between tumor cells and the healthy immune cells in their environment. Although it’s known that this communication is…
Researcher Spotlight: Todd Fehniger, MD, PhD washington university school of medicine Natural killer (NK) cells are a type of immune cell that fight infections and cancer cells. Using advanced techniques for single-cell analysis, Dr. Fehniger’s LRF research aims to study…
